{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:57:31Z","timestamp":1771657051805,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T00:00:00Z","timestamp":1456099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Immunol"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1038\/cmi.2015.100","type":"journal-article","created":{"date-parts":[[2016,2,22]],"date-time":"2016-02-22T12:14:51Z","timestamp":1456143291000},"page":"678-687","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The frequency and skewed T-cell receptor beta-chain variable patterns of peripheral CD4+CD25+ regulatory T-cells are associated with hepatitis B e antigen seroconversion of chronic hepatitis B patients during antiviral treatment"],"prefix":"10.1038","volume":"13","author":[{"given":"Jiezuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoping","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dangsheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongcui","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanjuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,22]]},"reference":[{"key":"BFcmi2015100_CR1","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1002\/hep.22898","volume":"49","author":"BJ McMahon","year":"2009","unstructured":"McMahon BJ . The natural history of chronic hepatitis B virus infection. Hepatology 2009; 49: S45\u201355 .","journal-title":"Hepatology"},{"key":"BFcmi2015100_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1741-7015-7-15","volume":"7","author":"S Lanini","year":"2009","unstructured":"Lanini S, Puro V, Lauria FN, Fusco FM, Nisii C, Ippolito G . Patient to patient transmission of hepatitis B virus: a systematic review of reports on outbreaks between 1992 and 2007. BMC Med 2009; 7: 15 .","journal-title":"BMC Med"},{"key":"BFcmi2015100_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/liv.12057","volume":"33","author":"Yun-Fan Liaw","year":"2013","unstructured":"Liaw YF . Impact of therapy on the outcome of chronic hepatitis B. Liver Int 2013; 33 Suppl 1:111\u2013115 .","journal-title":"Liver International"},{"issue":"10","key":"BFcmi2015100_CR4","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1111\/liv.12831","volume":"35","author":"Bulent Baran","year":"2015","unstructured":"Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Akyuz F et al. Tenofovir disoproxil fumarate has a substantial efficacy against multidrug resistant strains of hepatitis b virus. Liver Int 2015; 35: 2265\u20132274 .","journal-title":"Liver International"},{"key":"BFcmi2015100_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/hep.24078","volume":"53","author":"A Snow-Lampart","year":"2011","unstructured":"Snow-Lampart A, Chappell B, Curtis M, Zhu Y, Myrick F, Schawalder J et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011; 53: 763\u2013773 .","journal-title":"Hepatology"},{"key":"BFcmi2015100_CR6","doi-asserted-by":"crossref","unstructured":"Hung CH, Hu TH, Lu SN, Lee CM, Chen CH, Kee KM et al. Tenofovir versus entecavir in the treatment of chronic hepatitis B with severe acute exacerbation. Antimicrob Agents Chemother 2015; 59: 3168\u20133173 .","DOI":"10.1128\/AAC.00261-15"},{"key":"BFcmi2015100_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1053\/j.gastro.2012.07.014","volume":"143","author":"C Boni","year":"2012","unstructured":"Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology 2012; 143: 963\u2013973.e9 .","journal-title":"Gastroenterology"},{"key":"BFcmi2015100_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.clim.2008.07.029","volume":"129","author":"JN Stoop","year":"2008","unstructured":"Stoop JN, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL et al. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. Clin Immunol 2008; 129: 419\u2013427 .","journal-title":"Clin Immunol"},{"issue":"1","key":"BFcmi2015100_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.virol.2006.11.018","volume":"361","author":"Jeroen N. Stoop","year":"2007","unstructured":"Stoop JN, van der Molen RG, Kuipers EJ, Kusters JG, Janssen HL . Inhibition of viral replication reduces regulatory T cells and enhances the antiviral immune response in chronic hepatitis B. Virology 2007; 361: 141\u2013148 .","journal-title":"Virology"},{"key":"BFcmi2015100_CR10","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.3892\/mmr.2014.2042","volume":"9","author":"Z Yan","year":"2014","unstructured":"Yan Z, Zhou J, Zhang M, Fu X, Wu Y, Wang Y . Telbivudine decreases proportion of peripheral blood CD4+CD25+CD127 low T cells in parallel with inhibiting hepatitis B virus DNA. Mol Med Rep 2014; 9: 2024\u20132030 .","journal-title":"Mol Med Rep"},{"key":"BFcmi2015100_CR11","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10875-011-9509-7","volume":"31","author":"N TrehanPati","year":"2011","unstructured":"TrehanPati N, Kotillil S, Hissar SS, Shrivastava S, Khanam A, Sukriti S et al. Circulating Tregs correlate with viral load reduction in chronic HBV-treated patients with tenofovir disoproxil fumarate. J Clin Immunol 2011; 31: 509\u2013520 .","journal-title":"J Clin Immunol"},{"issue":"1","key":"BFcmi2015100_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.4049\/jimmunol.177.1.739","volume":"177","author":"D. Xu","year":"2006","unstructured":"Xu D, Fu J, Jin L, Zhang H, Zhou C, Zou Z et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J\u00a0Immunol 2006; 177: 739\u2013747 .","journal-title":"The Journal of Immunology"},{"key":"BFcmi2015100_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/cmi.2014.134","volume":"12","author":"M Attaf","year":"2015","unstructured":"Attaf M, Huseby E, Sewell AK . Alphabeta T cell receptors as predictors of health and disease. Cell Mol Immunol 2015; 12: 391\u2013399 .","journal-title":"Cell Mol Immunol"},{"key":"BFcmi2015100_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nri1292","volume":"4","author":"J Nikolich-Zugich","year":"2004","unstructured":"Nikolich-Zugich J, Slifka MK, Messaoudi I . The many important facets of T-cell repertoire diversity. Nat Rev Immunol 2004; 4: 123\u2013132 .","journal-title":"Nat Rev Immunol"},{"key":"BFcmi2015100_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/nri1977","volume":"6","author":"SJ Turner","year":"2006","unstructured":"Turner SJ, Doherty PC, McCluskey J, Rossjohn J . Structural determinants of T-cell receptor bias in immunity. Nat Rev Immunol 2006; 6: 883\u2013894 .","journal-title":"Nat Rev Immunol"},{"key":"BFcmi2015100_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/imr.12002","volume":"250","author":"Y Yin","year":"2012","unstructured":"Yin Y, Li Y, Mariuzza RA . Structural basis for self-recognition by autoimmune T-cell receptors. Immunol Rev 2012; 250: 32\u201348 .","journal-title":"Immunol Rev"},{"key":"BFcmi2015100_CR17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/1479-5876-10-193","volume":"10","author":"J Yang","year":"2012","unstructured":"Yang J, Yi P, Wei L, Xu Z, Chen Y, Tang L et al. Phenotypes and clinical significance of circulating CD4(+)CD25(+) regulatory T cells (Tregs) in patients with acute-on-chronic liver failure (ACLF). J Transl Med 2012; 10: 193 .","journal-title":"J Transl Med"},{"issue":"1","key":"BFcmi2015100_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1053\/j.gastro.2010.10.011","volume":"140","author":"E. Jenny Heathcote","year":"2011","unstructured":"Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132\u2013143 .","journal-title":"Gastroenterology"},{"key":"BFcmi2015100_CR19","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/1479-5876-12-183","volume":"12","author":"J Yang","year":"2014","unstructured":"Yang J, Chen J, Ye P, Jin L, Wu W, Sheng G et al. HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients. J Transl Med 2014; 12: 183 .","journal-title":"J Transl Med"},{"issue":"6","key":"BFcmi2015100_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1136\/gutjnl-2013-305138","volume":"63","author":"Ching-Lung Lai","year":"2013","unstructured":"Lai CL, Ahn SH, Lee KS, Um SH, Cho M, Yoon SK et al. Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut 2014; 63: 996\u20131004 .","journal-title":"Gut"},{"key":"BFcmi2015100_CR21","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/cmi.2014.12","volume":"11","author":"J Yang","year":"2014","unstructured":"Yang J, Chen J, He J, Xie Y, Zhu Y, Cao H et al. Profiling the repertoire of T-cell receptor beta-chain variable genes in peripheral blood lymphocytes from subjects who have recovered from acute hepatitis B virus infection. Cell Mol Immunol 2014; 11: 343\u2013354 .","journal-title":"Cell Mol Immunol"},{"key":"BFcmi2015100_CR22","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.tube.2013.05.007","volume":"93","author":"J Yang","year":"2013","unstructured":"Yang J, Xu K, Zheng J, Wei L, Fan J, Li L . Limited T cell receptor beta variable repertoire responses to ESAT-6 and CFP-10 in subjects infected with Mycobacterium tuberculosis. Tuberculosis (Edinb) 2013; 93: 529\u2013537 .","journal-title":"Tuberculosis (Edinb)"},{"key":"BFcmi2015100_CR23","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1574-695X.2012.00969.x","volume":"65","author":"J Yang","year":"2012","unstructured":"Yang J, Chen J, Mao H, Yi P, Yan D, He J et al. Skewed T-cell receptor beta chain variable gene (TCRBV) usage among different clinical types of patients with chronic HBV infection. FEMS Immunol Med Microbiol 2012; 65: 448\u2013455 .","journal-title":"FEMS Immunol Med Microbiol"},{"key":"BFcmi2015100_CR24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1742-4933-5-14","volume":"5","author":"A Schwanninger","year":"2008","unstructured":"Schwanninger A, Weinberger B, Weiskopf D, Herndler-Brandstetter D, Reitinger S, Gassner C et al. Age-related appearance of a CMV-specific high-avidity CD8+ T cell clonotype which does not occur in young adults. Immun Ageing 2008; 5: 14 .","journal-title":"Immun Ageing"},{"key":"BFcmi2015100_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.molimm.2007.07.038","volume":"45","author":"G Peng","year":"2008","unstructured":"Peng G, Li S, Wu W, Tan X, Chen Y, Chen Z . PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. Mol Immunol 2008; 45: 963\u2013970 .","journal-title":"Mol Immunol"},{"issue":"4","key":"BFcmi2015100_CR26","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1586\/egh.12.19","volume":"6","author":"Maria Buti","year":"2012","unstructured":"Buti M, Homs M . Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2012; 6: 413\u2013421 .","journal-title":"Expert Review of Gastroenterology & Hepatology"},{"issue":"4","key":"BFcmi2015100_CR27","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1128\/AAC.02600-12","volume":"57","author":"Bulent Baran","year":"2013","unstructured":"Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside\/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother 2013; 57: 1790\u20131796 .","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"BFcmi2015100_CR28","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1002\/hep.25879","volume":"56","author":"J Martinet","year":"2012","unstructured":"Martinet J, Leroy V, Dufeu-Duchesne T, Larrat S, Richard MJ, Zoulim F et al. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection. Hepatology 2012; 56: 1706\u20131718 .","journal-title":"Hepatology"},{"key":"BFcmi2015100_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/ni1181","volume":"6","author":"Y Belkaid","year":"2005","unstructured":"Belkaid Y, Rouse BT . Natural regulatory T cells in infectious disease. Nat Immunol 2005; 6: 353\u2013360 .","journal-title":"Nat Immunol"},{"key":"BFcmi2015100_CR30","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3760\/cma.j.issn.0366-6999.20120535","volume":"126","author":"H Ma","year":"2013","unstructured":"Ma H, Zhang HH, Wei L . Frequency of T-cell FoxP3(+) Treg and CD4(+)\/CD8(+) PD-1 expression is related to HBeAg seroconversion in hepatitis B patients on pegylated interferon. Chin Med J 2013; 126: 267\u2013273 .","journal-title":"Chin Med J"},{"issue":"2","key":"BFcmi2015100_CR31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.22065","volume":"47","author":"Michael W. Fried","year":"2008","unstructured":"Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428\u2013434 .","journal-title":"Hepatology"},{"key":"BFcmi2015100_CR32","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.jhep.2013.06.007","volume":"59","author":"WK Seto","year":"2013","unstructured":"Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF et al. Patterns of hepatitis B\u00a0surface antigen decline and HBV DNA\u00a0suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol 2013; 59: 709\u2013716 .","journal-title":"J Hepatol"},{"key":"BFcmi2015100_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","volume":"365","author":"HL Janssen","year":"2005","unstructured":"Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123\u2013129 .","journal-title":"Lancet"},{"key":"BFcmi2015100_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jhep.2010.07.046","volume":"54","author":"JG Reijnders","year":"2011","unstructured":"Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449\u2013454 .","journal-title":"J Hepatol"},{"key":"BFcmi2015100_CR35","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1158\/0008-5472.CAN-12-0277","volume":"72","author":"A Sainz-Perez","year":"2012","unstructured":"Sainz-Perez A, Lim A, Lemercier B, Leclerc C . The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res 2012; 72: 3557\u20133569 .","journal-title":"Cancer Res"},{"issue":"11","key":"BFcmi2015100_CR36","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1084\/jem.20141308","volume":"211","author":"Fei Duan","year":"2014","unstructured":"Duan F, Duitama J, Al Seesi S, Ayres CM, Corcelli SA, Pawashe AP et al. Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med 2014; 211: 2231\u20132248 .","journal-title":"The Journal of Experimental Medicine"},{"key":"BFcmi2015100_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/imr.12143","volume":"257","author":"RH Vonderheide","year":"2014","unstructured":"Vonderheide RH, June CH . Engineering T cells for cancer: our synthetic future. Immunol Rev 2014; 257: 7\u201313 .","journal-title":"Immunol Rev"},{"key":"BFcmi2015100_CR38","doi-asserted-by":"publisher","first-page":"284ra256","DOI":"10.1126\/scitranslmed.aaa1983","volume":"7","author":"J Cuende","year":"2015","unstructured":"Cuende J, Lienart S, Dedobbeleer O, van der Woning B, De Boeck G, Stockis J et al. Monoclonal antibodies against GARP\/TGF-beta1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo. Sci Transl Med 2015; 7: 284ra256 .","journal-title":"Sci Transl Med"},{"issue":"1","key":"BFcmi2015100_CR39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.canlet.2015.10.009","volume":"370","author":"Haidong Tang","year":"2016","unstructured":"Tang H, Qiao J, Fu YX . Immunotherapy and tumor microenvironment. Cancer Lett 2016; 370: 85\u201390","journal-title":"Cancer Letters"},{"key":"BFcmi2015100_CR40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1111\/bjh.12981","volume":"166","author":"W Qasim","year":"2014","unstructured":"Qasim W, Thrasher AJ . Progress and prospects for engineered T cell therapies. Br J Haematol 2014; 166: 818\u2013829 .","journal-title":"Br J Haematol"},{"key":"BFcmi2015100_CR41","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nsmb.2817","volume":"21","author":"J Petersen","year":"2014","unstructured":"Petersen J, Montserrat V, Mujico JR, Loh KL, Beringer DX, van Lummel M et al. T-cell receptor recognition of HLA-DQ2-gliadin complexes associated with celiac disease. Nat Struct Mol Biol 2014; 21: 480\u2013488 .","journal-title":"Nat Struct Mol Biol"},{"key":"BFcmi2015100_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/icb.2010.139","volume":"89","author":"JJ Miles","year":"2011","unstructured":"Miles JJ, Douek DC, Price DA . Bias in the alphabeta T-cell repertoire: implications for disease pathogenesis and vaccination. Immunol Cell Biol 2011; 89: 375\u2013387 .","journal-title":"Immunol Cell Biol"},{"key":"BFcmi2015100_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.clim.2005.02.018","volume":"115","author":"C Baecher-Allan","year":"2005","unstructured":"Baecher-Allan C, Wolf E, Hafler DA . Functional analysis of highly defined, FACS-isolated populations of human regulatory CD4+ CD25+ T cells. Clin Immunol 2005; 115: 10\u201318 .","journal-title":"Clin Immunol"},{"key":"BFcmi2015100_CR44","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/cmi.2015.10","volume":"12","author":"Z Li","year":"2015","unstructured":"Li Z, Li D, Tsun A, Li B . FOXP3(+) regulatory T cells and their functional regulation. Cell Mol Immunol 2015; 12: 558\u2013565 .","journal-title":"Cell Mol Immunol"}],"container-title":["Cellular & Molecular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cmi2015100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cmi2015100","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cmi.2015.100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cmi2015100.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:18:50Z","timestamp":1748783930000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cmi2015100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,22]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,9]]}},"alternative-id":["BFcmi2015100"],"URL":"https:\/\/doi.org\/10.1038\/cmi.2015.100","relation":{},"ISSN":["1672-7681","2042-0226"],"issn-type":[{"value":"1672-7681","type":"print"},{"value":"2042-0226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,22]]},"assertion":[{"value":"11 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}